Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy

被引：2

作者：

de Leon, Jeremiah F. ^{[1
]}

Kneebone, Andrew ^{[2
,3
]}

Gebski, Val ^{[3
,4
,5
]}

Cross, Shamira ^{[5
,6
]}

Do, Viet ^{[6
,7
,8
]}

Hayden, Amy ^{[5
,6
]}

Ngo, Diana ^{[7
]}

Sidhom, Mark ^{[7
,8
]}

Turner, Sandra ^{[3
,5
]}

机构：

[1] Illawarra Canc Care Ctr, Dept Radiat Oncol, 348 Crown St, Wollongong, NSW 2500, Australia

[2] Northern Sydney Canc Ctr, Sydney, NSW, Australia

[3] Univ Sydney, Sydney, NSW, Australia

[4] NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[5] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia

[6] Nepean Canc Ctr, Sydney, NSW, Australia

[7] Liverpool & Macarthur Canc Therapy Ctr, Sydney, NSW, Australia

[8] Univ New South Wales, Sydney, NSW, Australia

来源：

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY | 2019年 / 63卷 / 01期

关键词：

prostate cancer; radiotherapy; DOSE CONFORMAL RADIOTHERAPY; PHASE-III TRIAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; ANDROGEN-DEPRIVATION; ESCALATION TRIAL; SURVIVAL; SURGERY; MEN; INTERMEDIATE;

D O I：

10.1111/1754-9485.12797

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Introduction: Optimal definitive treatment of prostate cancer is controversial, especially in high-risk patients. We report the largest prospective cohort of Australian patients treated with radiotherapy for localised prostate cancer. Methods: One thousand, one hundred and twenty-one patients with prostate cancer were prospectively registered and treated to a dose of 70-74 Gy. Patients were classified as low, intermediate or high risk based on PSA, clinical staging and Gleason score. Intermediate-risk patients were treated with 0-6 months of hormonal therapy (ADT) and high-risk patients were offered neoadjuvant and adjuvant ADT. Overall survival (OS) and biochemical relapsefree survival (bNED) were calculated using the Kaplan-Meier method. Results: Median follow-up was 92 months. Eight-year OS and bNED were 78.4% and 68.1% respectively in the entire cohort. OS for the low, intermediate and high-risk groups was 84.5%, 78.4% and 68% respectively. For these risk groups, bNED was 80.3%, 65.7% and 53.7% respectively. In the intermediate and high-risk group, OS and bNED decreased with increasing number of risk factors. Conclusion: Definitive radiotherapy is an effective treatment for prostate cancer, including in high-risk cases.

引用

页码：116 / 123

页数：8

共 46 条

[11] Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial [J].

Denham, JW ;

Steigler, A ;

Lamb, DS ;

Joseph, D ;

Mameghan, H ;

Turner, S ;

Matthews, J ;

Franklin, I ;

Atkinson, C ;

North, J ;

Poulsen, M ;

Christie, D ;

Spry, NA ;

Tai, KH ;

Wynne, C ;

Duchesne, G ;

Kovacev, O ;

D'Este, C .

LANCET ONCOLOGY, 2005, 6 (11) :841-850

[12] Poorly differentiated prostate cancer treated with radical prostatectomy: Long-term outcome and incidence of pathological downgrading [J].

Donohue, John F. ;

Bianco, Fernando J., Jr. ;

Kuroiwa, Kentaro ;

Vickers, Andrew J. ;

Wheeler, Thomas M. ;

Scardino, Peter T. ;

Reuter, Victor A. ;

Eastham, James A. .

JOURNAL OF UROLOGY, 2006, 176 (03) :991-995

[13] Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate-to High-Risk Prostate Cancer [J].

Dorth, Jennifer A. ;

Lee, W. Robert ;

Chino, Junzo ;

Abouassaly, Robert ;

Ellis, Rodney J. ;

Myers, Evan R. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (02) :383-390

[14] Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer [J].

Fletcher, Sophie G. ;

Mills, Stacey E. ;

Smolkin, Mark E. ;

Theodorescu, Dan .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (04) :1092-1099

[15]

Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th

[16] 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer [J].

Hamdy, F. C. ;

Donovan, J. L. ;

Lane, J. A. ;

Mason, M. ;

Metcalfe, C. ;

Holding, P. ;

Davis, M. ;

Peters, T. J. ;

Turner, E. L. ;

Martin, R. M. ;

Oxley, J. ;

Robinson, M. ;

Staffurth, J. ;

Walsh, E. ;

Bollina, P. ;

Catto, J. ;

Doble, A. ;

Doherty, A. ;

Gillatt, D. ;

Kockelbergh, R. ;

Kynaston, H. ;

Paul, A. ;

Powell, P. ;

Prescott, S. ;

Rosario, D. J. ;

Rowe, E. ;

Neal, D. E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1415-1424

[17] Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 [J].

Hanks, GE ;

Pajak, TF ;

Porter, A ;

Grignon, D ;

Brereton, H ;

Venkatesan, V ;

Horwitz, EM ;

Lawton, C ;

Rosenthal, SA ;

Sandler, HM ;

Shipley, WU .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3972-3978

[18] Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study [J].

Haworth, Annette ;

Kearvell, Rachel ;

Greer, Peter B. ;

Hooton, Ben ;

Denham, James W. ;

Lamb, David ;

Duchesne, Gillian ;

Murray, Judy ;

Joseph, David .

RADIOTHERAPY AND ONCOLOGY, 2009, 90 (03) :299-306

[19]

Jeldres C, 2009, CUAJ-CAN UROL ASSOC, V3, P13

[20] Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer [J].

Kalbasi, Anusha ;

Li, Jiaqi ;

Berman, Abigail T. ;

Swisher-McClure, Samuel ;

Smaldone, Marc ;

Uzzo, Robert G. ;

Small, Dylan S. ;

Mitra, Nandita ;

Bekelman, Justin E. .

JAMA ONCOLOGY, 2015, 1 (07) :897-906

← 1 2 3 4 5 →